Thanks. I agree. Last year, they identified over 110 novel solid tumour targets in samples from patients who responded to different types of immunotherapy, such as TIL. Taken together with them covering the most common HLAs, they could end up with the largest library of TCRs in the space.
Recent TCRX News
- Form ARS - Annual Report to Security Holders • Edgar (US Regulatory) • 04/17/2026 11:32:05 AM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 04/17/2026 11:30:29 AM
- TScan Therapeutics to Participate in the 25th Annual Needham Virtual Healthcare Conference • GlobeNewswire Inc. • 04/08/2026 11:00:00 AM
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 04/07/2026 08:30:19 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 04/02/2026 11:30:07 AM
- Combination Therapies Reshape Oncology: A $748B Market Shifts Standard of Care • PR Newswire (Canada) • 03/19/2026 02:00:00 PM
- Combination Therapies Reshape Oncology: A $748B Market Shifts Standard of Care • PR Newswire (US) • 03/19/2026 02:00:00 PM
- Form S-8 - Securities to be offered to employees in employee benefit plans • Edgar (US Regulatory) • 03/04/2026 12:42:13 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 03/04/2026 12:30:55 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/04/2026 12:15:28 PM
- TScan Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update • GlobeNewswire Inc. • 03/04/2026 12:00:00 PM
- TScan Therapeutics Completes Enrollment in Cohort C of Phase 1 ALLOHA™ Trial and Announces FDA Clearance of Investigational New Drug Applications for Heme Candidates TSC-102-A01 and TSC-102-A03 • GlobeNewswire Inc. • 02/26/2026 12:00:00 PM
- TScan Therapeutics to Participate in the TD Cowen 46th Annual Health Care Conference • GlobeNewswire Inc. • 02/25/2026 12:00:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/22/2026 10:30:20 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/22/2026 10:27:49 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/12/2026 12:30:19 PM
- Smart Money Abandons Single-Asset Risk: Why Platforms Now Command 60% of Pharma Pipelines • PR Newswire (US) • 12/19/2025 12:55:00 PM
- Smart Money Abandons Single-Asset Risk: Why Platforms Now Command 60% of Pharma Pipelines • PR Newswire (Canada) • 12/19/2025 12:55:00 PM
- TScan Therapeutics Announces Positive Updated Data from the ALLOHA™ Phase 1 Heme Trial at the 67th American Society of Hematology Annual Meeting and Exposition • GlobeNewswire Inc. • 12/06/2025 10:30:00 PM
- Blood Cancer Therapeutics Reach Critical Commercial and Clinical Inflection Points • PR Newswire (Canada) • 12/04/2025 05:20:00 PM
- Blood Cancer Therapeutics Reach Critical Commercial and Clinical Inflection Points • PR Newswire (US) • 12/04/2025 05:20:00 PM
- TScan Therapeutics to Host Virtual KOL Event to Discuss Clinical Updates from the ALLOHA™ Phase 1 Trial and Future Market Opportunities • GlobeNewswire Inc. • 12/03/2025 09:05:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/26/2025 09:15:12 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/12/2025 12:30:45 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/12/2025 12:15:30 PM
